This study used a multicenter federated research network to compare clinical outcomes of COVID-19 in patients with SOT to a propensity matched cohort of patients without SOT. 2,307 SOT recipients and 231,047 non-transplant patients with COVID-19 were identified. Transplant patients were more likely to be male, older, have a BMI >30kg/m2, and have comorbid hypertension, diabetes, nicotine dependence, heart failure and ischemic heart disease compared to non-transplant group (p-value <0.05). 1:1 matching was performed for diabetes, hypertension, chronic lung diseases, race, nicotine dependence, heart failure, ischemic heart disease and gender. There was no difference in the composite outcome of intubation or mechanical ventilation at 30 days (RR 1.04, 95% CI: 0.86–1.26) or 60 days (RR 1.03, 95% CI: 0.86-1.24) between the two groups. Hospitalization rate was higher in the transplant cohort (30.97% vs 25.47%, RR 1.22, 95% CI: 1.11-1.34). There was no difference in mortality at 30 days (6.45% vs 5.29%, RR 1.22, 95% CI: 0.88–1.68) or 60 days post diagnosis (RR 1.05, 95% CI: 0.83–1.32). More patients in the SOT group developed acute renal injury compared to non-SOT cohort (24.73% vs 14.29%; RR 1.73, 95% CI: 1.53-1.96).